Anavex Life Sciences

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2006-01-01

Employees: 40

Market Cap: $515.5M

Website: http://www.anavex.com

Introduction: Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Clinical Trials

A Study of ANAVEX3-71 in Adults With Schizophrenia

Phase 2

Recruiting

Conditions: Schizophrenia

Interventions: Drug: ANAVEX3-71 oral capsules
Drug: Placebo oral capsules

First Posted Date: 2024-02-07

Last Posted Date: 2024-03-20

Lead Sponsor: Anavex Life Sciences Corp.

Target Recruit Count: 40

Registration Number: NCT06245213

Locations: 🇺🇸
CenExel Hassman Research Institute, Marlton, New Jersey, United States

OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001

Phase 2

Completed

Conditions: Parkinson Disease Dementia

Interventions: Drug: ANAVEX2-73

First Posted Date: 2020-10-05

Last Posted Date: 2022-08-01

Lead Sponsor: Anavex Life Sciences Corp.

Target Recruit Count: 132

Registration Number: NCT04575259

Locations: 🇪🇸
Hospital del Henares, Coslada, Spain
🇪🇸
Hospital Clínico San Carlos, Madrid, Spain
🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain

and more 7 locations

Phase 1 Study of ANAVEX3-71

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ANAVEX3-71
Drug: Placebo

First Posted Date: 2020-06-23

Last Posted Date: 2022-01-19

Lead Sponsor: Anavex Life Sciences Corp.

Target Recruit Count: 36

Registration Number: NCT04442945

Locations: 🇦🇺
CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia

OLE of Phase 2b/3 Study ANAVEX2-73-AD-004

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: ANAVEX2-73

First Posted Date: 2020-03-19

Last Posted Date: 2024-08-12

Lead Sponsor: Anavex Life Sciences Corp.

Target Recruit Count: 300

Registration Number: NCT04314934

Locations: 🇨🇦
Toronto Memory Program, Toronto, Ontario, Canada
🇩🇪
Charite University Medicine, Berlin, Germany
🇦🇺
Gold Coast Memory Disorders Clinic, Southport, Quennsland, Australia

and more 30 locations

ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome

Phase 2

Completed

Conditions: Rett Syndrome

Interventions: Drug: Placebo oral liquid
Drug: ANAVEX2-73 oral liquid

First Posted Date: 2020-03-11

Last Posted Date: 2023-08-21

Lead Sponsor: Anavex Life Sciences Corp.

Target Recruit Count: 92

Registration Number: NCT04304482

Locations: 🇬🇧
King's College of London, London, United Kingdom
🇦🇺
Queensland Children's Hospital, Brisbane, Queensland, Australia
🇦🇺
Austin Health, Melbourne, Victoria, Australia

and more 9 locations

ANAVEX2-73 Study in Patients With Rett Syndrome

Phase 3

Completed

Conditions: Rett Syndrome

Interventions: Drug: ANAVEX2-73
Drug: Placebo

First Posted Date: 2019-05-08

Last Posted Date: 2022-01-27

Lead Sponsor: Anavex Life Sciences Corp.

Target Recruit Count: 33

Registration Number: NCT03941444

Locations: 🇬🇧
Manchester CGM, St. Mary's Hospital, Manchester, UK, United Kingdom
🇦🇺
HammondCare, Greenwich, New South Wales, Australia
🇬🇧
King's College of London, London, UK, United Kingdom

and more 4 locations

ANAVEX2-73 for Treatment of Early Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: High dose ANAVEX2-73
Drug: Mid dose ANAVEX2-73
Drug: Placebo oral capsule

First Posted Date: 2019-01-02

Last Posted Date: 2022-07-14

Lead Sponsor: Anavex Life Sciences Corp.

Target Recruit Count: 509

Registration Number: NCT03790709

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇦🇺
The Royal Adelaide Hospital (RAH) and The Queen Elizabeth Hospital (TQEH), Adelaide, South Australia, Australia
🇨🇦
Toronto Memory Program, Toronto, Ontario, Canada

and more 39 locations

ANAVEX2-73 Study in Parkinson's Disease Dementia

Phase 2

Completed

Conditions: Parkinsons Disease With Dementia

Interventions: Drug: Mid dose ANAVEX2-73
Drug: High dose ANAVEX2-73
Drug: Placebo oral capsule

First Posted Date: 2018-12-13

Last Posted Date: 2020-10-22

Lead Sponsor: Anavex Life Sciences Corp.

Target Recruit Count: 132

Registration Number: NCT03774459

Locations: 🇦🇺
KaRa MINDS, Macquarie Park, Australia
🇪🇸
Hospital Santa Caterina, Girona, Spain
🇪🇸
Clinica Ruber Internacional, Madrid, Spain

and more 22 locations

Study of ANAVEX2-73 in Patients With Rett Syndrome

Phase 2

Completed

Conditions: Rett Syndrome

Interventions: Drug: Placebo
Drug: ANAVEX2-73

First Posted Date: 2018-11-29

Last Posted Date: 2021-01-12

Lead Sponsor: Anavex Life Sciences Corp.

Target Recruit Count: 31

Registration Number: NCT03758924

Locations: 🇺🇸
UAB | The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 5 locations

An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: ANAVEX2-73

First Posted Date: 2016-04-29

Last Posted Date: 2021-01-12

Lead Sponsor: Anavex Life Sciences Corp.

Target Recruit Count: 21

Registration Number: NCT02756858

Locations: 🇦🇺
Melbourne Health - The Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇦🇺
Nucleus Network- Centre for Clinical Studies, Melbourne, Victoria, Australia
🇦🇺
Austin Health - Heidelberg Repatriation Hospital, Melbourne, Victoria, Australia

and more 2 locations

Home Terms & Conditions Privacy Policy